Cabergoline treatment in acromegaly: Cons

Endocrine

Volumn 46, Issue 2, 2014, Pages 220-225

  Kasuki, Leandro ^a,b   Vieira Neto, Leonardo ^a,c   Gadelha, Mônica R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Bonsucesso Federal Hospital   (Brazil)

^c Lagoa Federal Hospital   (Brazil)

Author keywords

Acromegaly; Cabergoline; Dopamine agonists; Treatment

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PEGVISOMANT; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; ERGOLINE DERIVATIVE; OCTREOTIDE;

ACROMEGALY; ADJUVANT THERAPY; ADVERSE OUTCOME; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; HEART VALVE REGURGITATION; HUMAN; IMPULSE CONTROL DISORDER; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION;

ACROMEGALY; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ERGOLINES; HUMANS; OCTREOTIDE;

EID: 84902357782     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0183-4     Document Type: Review

References (48)

1. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina, Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94(5), 1509-1517 (2009)
2. L. Vieira Neto, J. Abucham, L.A. Araujo, C.L. Boguszewski, M.D. Bronstein, M. Czepielewski, R.S. Jallad, N.R. Musolino, L.A. Naves, A. Ribeiro-Oliveira Junior, L. Vilar, S. Faria Mdos, M.R. Gadelha, Recommendations of neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq. Bras. Endocrinol. Metab. 55(2), 91-105 (2011)
3. R. Abs, J. Verhelst, D. Maiter, K. Van Acker, F. Nobels, J.L. Coolens, C. Mahler, A. Beckers, Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83(2), 374-378 (1998)
4. R. Cozzi, R. Attanasio, M. Barausse, D. Dallabonzana, P. Orlandi, N. Da Re, V. Branca, G. Oppizzi, D. Gelli, Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur. J. Endocrinol. 139(5), 516-521 (1998)
5. P.U. Freda, C.M. Reyes, A.T. Nuruzzaman, R.E. Sundeen, A.G. Khandji, K.D. Post, Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 7(1), 21-30 (2004)
6. B. Gatta, D.H. Hau, B. Catargi, P. Roger, A. Tabarin, Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin. Endocrinol. (Oxf) 63(4), 477-478 (2005)
7. P. Nomikos, M. Buchfelder, R. Fahlbusch, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur. J. Endocrinol. 152(3), 379-387 (2005)
8. P.U. Freda, L. Katznelson, A.J. van der Lely, C.M. Reyes, S. Zhao, D. Rabinowitz, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90(8), 4465-4473 (2005)
9. A. Mestron, S.M. Webb, R. Astorga, P. Benito, M. Catala, S. Gaztambide, J.M. Gomez, I. Halperin, T. Lucas-Morante, B. Moreno, G. Obiols, P. de Pablos, C. Paramo, A. Pico, E. Torres, C. Varela, J.A. Vazquez, J. Zamora, M. Albareda, M. Gilabert, Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur. J. Endocrinol. 151(4), 439-446 (2004)
10. M. Mercado, F. Borges, H. Bouterfa, T.C. Chang, A. Chervin, A.J. Farrall, A. Patocs, S. Petersenn, J. Podoba, M. Safari, J. Wardlaw, S.B.S. Group, A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin. Endocrinol. (Oxf) 66 (6), 859-868 (2007)
11. S. Melmed, D. Cook, J. Schopohl, M.I. Goth, K.S. Lam, J. Marek, Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13(1), 18-28 (2010)
12. W. Drake, C. Stiles, T. Howlett, A. Toogood, J. Bevan, R. Steeds, A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J. Clin. Endocrinol. Metab. 99(1), 90-96 (2013)
13. A. Giustina, I. Karamouzis, I. Patelli, G. Mazziotti, Octreotide for acromegaly treatment: a reappraisal. Expert Opin. Pharmacother. 14(17), 2433-2447 (2013)
14. A. Colao, P. Cappabianca, P. Caron, E. De Menis, A.J. Farrall, M.R. Gadelha, A. Hmissi, A. Rees, M. Reincke, M. Safari, G. T'Sjoen, H. Bouterfa, R.C. Cuneo, Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin. Endocrinol. (Oxf) 70(5), 757-768 (2009)
15. L. Sandret, P. Maison, P. Chanson, Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96(5), 1327-1335 (2011)
16. A. Colao, D. Ferone, P. Marzullo, A. Di Sarno, G. Cerbone, F. Sarnacchiaro, S. Cirillo, B. Merola, G. Lombardi, Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab. 82(2), 518-523 (1997)
17. V.J. Moyes, K.A. Metcalfe, W.M. Drake, Clinical use of cabergoline as primary and adjunctive treatment for acromegaly. Eur. J. Endocrinol. 159(5), 541-545 (2008)
18. T.A. Howlett, D. Willis, G. Walker, J.A. Wass, P.J. Trainer, Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin. Endocrinol. (Oxf) 79(5), 689-699 (2013)
19. A. Giustina, G. Mazziotti, V. Torri, M. Spinello, I. Floriani, S. Melmed, Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 7(5), e36411 (2012)
20. G. Mazziotti, A. Giustina, Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13(1), 60-67 (2010)
21. M. Sherlock, E. Fernandez-Rodriguez, A.A. Alonso, R.C. Reulen, J. Ayuk, R.N. Clayton, G. Holder, M.C. Sheppard, A. Bates, P.M. Stewart, Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J. Clin. Endocrinol. Metab. 94(4), 1255-1263 (2009)
22. R. Cozzi, R. Attanasio, S. Lodrini, G. Lasio, Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf) 61(2), 209-215 (2004)
23. R.S. Jallad, M.D. Bronstein, Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology 90(1), 82-92 (2009)
24. P. Marzullo, D. Ferone, C. Di Somma, R. Pivonello, M. Filippella, G. Lombardi, A. Colao, Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1(2), 115-120 (1999)
25. D. Selvarajah, J. Webster, R. Ross, J. Newell-Price, Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol. 152(4), 569-574 (2005)
26. L. Vilar, M.F. Azevedo, L.A. Naves, L.A. Casulari, J.L. Albuquerque, R.M. Montenegro, R.M. Montenegro Jr, P. Figueiredo, G.C. Nascimento, M.S. Faria, Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 14(2), 148-156 (2011)
27. P. Mattar, M.R. Alves Martins, J. Abucham, Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology 92(2), 120-127 (2010)
28. K. Suda, N. Inoshita, G. Iguchi, H. Fukuoka, M. Takahashi, H. Nishizawa, M. Yamamoto, S. Yamada, Y. Takahashi, Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr. J. 60(4), 507-515 (2013)
29. S.J. Neggers, A.J. van der Lely, Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Hormon IGF Res 21(3), 129-133 (2011)
30. S.J. Neggers, W.W. de Herder, J.A. Janssen, R.A. Feelders, A.J. van der Lely, Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur. J. Endocrinol. 160(4), 529-533 (2009)
31. S.J. Neggers, M.O. van Aken, J.A. Janssen, R.A. Feelders, W.W. de Herder, A.J. van der Lely, Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 92(12), 4598-4601 (2007)
32. E. Resmini, P. Dadati, J.L. Ravetti, G. Zona, R. Spaziante, A. Saveanu, P. Jaquet, M.D. Culler, F. Bianchi, A. Rebora, F. Minuto, D. Ferone, Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J. Clin. Endocrinol. Metab. 92(5), 1592-1599 (2007)
33. M. Gola, S. Bonadonna, G. Mazziotti, G. Amato, A. Giustina, Resistance to somatostatin analogs in acromegaly: an evolving concept? J. Endocrinol. Invest. 29 (1), 86-93 (2006)
34. C.E. Higham, A.B. Atkinson, S. Aylwin, M. Bidlingmaier, W.M. Drake, A. Lewis, N.M. Martin, V. Moyes, J. Newell-Price, P.J. Trainer, Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J. Clin. Endocrinol. Metab. 97(4), 1187-1193 (2012)
35. I. Bernabeu, C. Alvarez-Escola, A.E. Paniagua, T. Lucas, I. Pavon, J.M. Cabezas-Agricola, F.F. Casanueva, M. Marazuela, Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16(1), 101-108 (2013)
36. J. Martinkova, L. Trejbalova, M. Sasikova, J. Benetin, P. Valkovic, Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin. Neuropharmacol. 34(5), 179-181 (2011)
37. L. Bancos, M.R. Nannenga, J.M. Bostwick, M.H. Silber, D. Erickson, T.B. Nippoldt, Impulse control disorders in patients with dopamine agonist-treated prolactinomas and non-functioning pituitary adenomas: a case-control study. Clin. Endocrinol. (Oxf) (2013). doi:10.1111/cen.12375
38. R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, G. Pezzoli, Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New Engl. J. Med. 356 (1), 39-46 (2007)
39. R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, E. Garbe, Dopamine agonists and the risk of cardiac-valve regurgitation. New Engl. J. Med. 356(1), 29-38 (2007)
40. L. Maione, C. Garcia, A. Bouchachi, N. Kallel, P. Maison, S. Salenave, J. Young, P. Assayag, P. Chanson, No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J. Clin. Endocrinol. Metab. 97(9), E1714-E1719 (2012)
41. R. De Vecchis, C. Esposito, C. Ariano, Cabergoline use and risk of fibrosis and insufficiency of cardiac valves: meta-analysis of observational studies. Herz 38(8), 868-880 (2013)
42. R.S. Auriemma, R. Pivonello, Y. Perone, L.F. Grasso, L. Ferreri, C. Simeoli, D. Iacuaniello, M. Gasperi, A. Colao, Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur. J. Endocrinol. 169(3), 359-366 (2013)
43. A. Colao, M. Galderisi, A. Di Sarno, M. Pardo, M. Gaccione, M. D'Andrea, E. Guerra, R. Pivonello, G. Lerro, G. Lombardi, Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J. Clin. Endocrinol. Metab. 93 (10), 3777-3784 (2008)
44. A. Elenkova, R. Shabani, K. Kalinov, S. Zacharieva, Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur. J. Endocrinol. 167(1), 17-25 (2012)
45. A.M. Pereira, S.W. van Thiel, J.R. Lindner, F. Roelfsema, E.E. van der Wall, H. Morreau, J.W. Smit, J.A. Romijn, J.J. Bax, Increased prevalence of regurgitant valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab. 89(1), 71-75 (2004)
46. A.A. van der Klaauw, J.J. Bax, F. Roelfsema, G.B. Bleeker, E.R. Holman, E.P. Corssmit, E.E. van der Wall, J.W. Smit, J.A. Romijn, A.M. Pereira, Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Hormon. IGF Res. 16(2), 101-107 (2006)
47. A. Colao, L. Spinelli, P. Marzullo, R. Pivonello, M. Petretta, C. Di Somma, G. Vitale, D. Bonaduce, G. Lombardi, High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J. Clin. Endocrinol. Metab. 88(7), 3196-3201 (2003)
48. C. Izgi, H. Feray, C. Cevik, Y. Saltan, D. Mansuroglu, K. Nugent, Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. J. Heart Valve Dis. 19(6), 797-800 (2010)